UM1 Supplement for Early Therapeutic Trials with Phase 2 Intent

UM1 补充用于具有 2 期目的的早期治疗试验

基本信息

批准号：
9095812
负责人：
MICHAEL R GREVER
金额：
$ 86.13万
依托单位：
OHIO STATE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-03-28 至 2020-02-29
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9095812
关键词：
Antineoplastic Agents Appalachian Region Biological Response Modifier Therapy Blood Bone Marrow Neoplasms Cancer Burden Cancer Center Cancer Patient Clinic Clinical Clinical Trials Clinics and Hospitals Comprehensive Cancer Center Data Data Collection Development Dose Drug Kinetics Evaluation Generations Goals Grant Hematologic Neoplasms Image Incidence Institutes Institution Kentucky Laboratory Research Malignant Neoplasms Maximum Tolerated Dose Medical center Metabolism Modality Molecular Target National Cancer Institute New Agents Normal tissue morphology Ohio Outcome Parents Patients Pharmaceutical Preparations Pharmacodynamics Pharmacy Schools Phase Phase II Clinical Trials Population Publications Reporting Research Research Infrastructure Resistance Resources Safety Solid Neoplasm Structure Technology Therapeutic Therapeutic Agents Therapeutic Trials Tissues Toxic effect Translational Research Underserved Population Universities University Hospitals West Virginia anticancer research anticancer treatment antitumor effect base cancer therapy disadvantaged population imaging modality insight member mortality named group novel novel anticancer drug novel therapeutics peer predicting response programs public health relevance therapeutic evaluation treatment center

Antineoplastic Agents Appalachian Region Biological Response Modifier Therapy Blood Bone Marrow Neoplasms Cancer Burden Cancer Center Cancer Patient Clinic Clinical Clinical Trials Clinics and Hospitals Comprehensive Cancer Center Data Data Collection Development Dose Drug Kinetics Evaluation Generations Goals Grant Hematologic Neoplasms Image Incidence Institutes Institution Kentucky Laboratory Research Malignant Neoplasms Maximum Tolerated Dose Medical center Metabolism Modality Molecular Target National Cancer Institute New Agents Normal tissue morphology Ohio Outcome Parents Patients Pharmaceutical Preparations Pharmacodynamics Pharmacy Schools Phase Phase II Clinical Trials Population Publications Reporting Research Research Infrastructure Resistance Resources Safety Solid Neoplasm Structure Technology Therapeutic Therapeutic Agents Therapeutic Trials Tissues Toxic effect Translational Research Underserved Population Universities University Hospitals West Virginia anticancer research anticancer treatment antitumor effect base cancer therapy disadvantaged population imaging modality insight member mortality named group novel novel anticancer drug novel therapeutics peer predicting response programs public health relevance therapeutic evaluation treatment center

展开

项目摘要

DESCRIPTION (provided by applicant): The overall goal of this proposal is to provide a resource to the OSU UM1 (P.I. Michael Grever) for the conduct of Phase 2 clinical trials of National Cancer Institute (NCI) sponsored agents, to evaluate biologic effects of these agents on their molecular targets, to evaluate other relevant biologic effects, and to determine clinical relevant outcomes/correlates of efficacy and toxicity. The Ohio State University NCI-designated Comprehensive Cancer Center (OSUCCC) and its affiliated hospitals and clinics generate a resource of more than 5600 new analytic cancer patients per year. For this supplement proposal, the OSUCCC is partnering with other large cancer research and treatment centers in the State of Ohio: Seidman Cancer Center of University Hospitals Case Medical Center and The Cleveland Clinic Taussig Cancer Institute, consortium members of the NCI-designated Case Comprehensive Cancer Center at Case Western Reserve University (another 10,000 analytic new cancer patients per year) and the newly NCI-designated Markey Cancer Center (MCC) at the University of Kentucky (UK). With the latter institution that provides geographical proximity, we can now provide patients the opportunity for Phase 2 trials in a contiguous region (Ohio-Kentucky-West Virginia corridor) with access to novel therapeutics. It importantly incorporates a heavily underserved and special population (patients from the Central Appalachian Region) to the biological and therapeutic evaluation of novel targets. Access to a top rated school of pharmacy at UK, now strengthens further our translational science expertise.

DESCRIPTION (provided by applicable): The overall goal of this proposal is to provide a resource to the OSU UM1 (P.I. Michael Grever) for the conduct of Phase 2 clinical trials of National Cancer Institute (NCI) sponsored agents, to evaluate biologic effects of these agents on their molecular targets, to evaluate other relevant biologic effects, and to determine clinical relevant outcomes/correlates of effectiveness and toxicity.俄亥俄州立大学NCI指定的综合癌症中心（OSUCCC）及其会员医院和诊所每年产生5600多名新的分析癌症患者的资源。 For this supplement proposal, the OSUCCC is partnering with other large cancer research and treatment centers in the State of Ohio: Seidman Cancer Center of University Hospitals Case Medical Center and The Cleveland Clinic Taussig Cancer Institute, consortium members of the NCI-designated Case Comprehensive Cancer Center at Case Western Reserve University (another 10,000 analytic new cancer patients per year) and the newly NCI-designated Markey Cancer Center (MCC) at the University of肯塔基州（英国）。通过提供地理位置的后一种机构，我们现在可以为患者提供在连续区域（俄亥俄州 - 肯塔基州弗吉尼亚走廊）中进行2期试验的机会，并获得了新的治疗。重要的是，它纳入了一个服务不足和特殊人群（来自阿巴拉契亚中部地区的患者），以对新目标的生物学和治疗性评估。进入英国最高评价的药学院，现在可以进一步增强我们的转化科学专业知识。